Search
Capricor Therapeutics Inc
CAPRAdd to Watchlist
28.380USD
+0.430+1.54%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.30BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Capricor Therapeutics Inc is 8.22, ranking 151 out of 389 in the Biotechnology & Medical Research industry. The average price target is 47.50, with a high of 62.00 and a low of 20.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
54.111
Target Price
+90.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Capricor Therapeutics Inc
CAPR
9
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Capricor Therapeutics Inc's price target?
Analysts forecast that Capricor Therapeutics Inc's price target is USD 47.50, with the highest forecast at USD 62.00 and the lowest forecast at USD 20.00.
How have Capricor Therapeutics IncCAPR's recent earnings per share performed?
The market expectation was USD -0.59, while Capricor Therapeutics IncCAPR's earnings per share (EPS) for the previous quarter was USD -0.62. EPS for the next quarter is expected at USD -0.59.
What is the analyst rating for Capricor Therapeutics Inc?
Based on the ratings of Capricor Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
